However, despite the acceptable safety profile of BI-847325, its development has been halted due to insufficient drug exposure at the maximum tolerated dose (MTD) to achieve MEK inhibition in cancers such as liver, kidney, breast, and melanoma [16]. The gene discussed is MAP2K7; the disease is cancer.